Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. - Wikidata - wikimedia - TriplyDB

Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.

Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.

http://www.wikidata.org/entity/Q33396664

about

Uveal melanoma as a target for immune-therapy Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer Advances in immunotherapy for treatment of lung cancer Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma Uveal melanoma: From diagnosis to treatment and the science in between.Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).Management of uveal melanoma: a consensus-based provincial clinical practice guideline Isolated hepatic perfusion for ocular melanoma metastasis: registry data suggests a survival benefit.Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.Cutaneous melanoma: new advances in treatment.Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial Intra-arterial infusion and chemo-embolization for melanoma liver metastases.Current and emerging treatment options for uveal melanoma.The DecisionDx-UM Gene Expression Profile Test Provides Risk Stratification and Individualized Patient Care in Uveal Melanoma Corticosteroids augment BRAF inhibitor vemurafenib induced lymphopenia and risk of infection Positive and negative regulation of cellular immune responses in physiologic conditions and diseases Emerging options for the treatment of melanoma - focus on ipilimumab.Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis Checkpoint modulation in melanoma: an update on ipilimumab and future directions.Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis.The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis.Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.The biology of uveal melanoma Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2.Latest developments in the biology and management of uveal melanoma.Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options.Evolving systemic targeted therapy strategies in uveal melanoma and implications for ophthalmic management: a review.Update on Metastatic Uveal Melanoma: Progress and Challenges.Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.Ipilimumab in melanoma.Focus on cutaneous and uveal melanoma specificities.What have we learned from cancer immunotherapy in the last 3 years?Ruthenium-106 Brachytherapy with or without Additional Local Therapy Shows Favorable Outcome for Variable-Sized Choroidal Melanomas in Korean Patients.Acute Angle Closure Precipitated by Hemorrhage and Necrosis of a Large Uveal Melanoma in the Setting of Systemic Immunomodulatory Therapy.Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma.Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O).Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases

P2860

Q26747519-F9BA4B81-25A1-4746-988E-9B13C9CABDC7 Q26769713-5F8BDE28-6472-4A8A-8D48-AFE34F358CEF Q26778790-2FC8A1C4-1903-4506-97AB-9B9A92B2F194 Q26785746-7D551D38-5ABB-40E1-B38C-EAAD6CEBA66F Q28543960-856052F4-FFA0-4E06-9FFF-4AC33A66DE1F Q30251762-5F558020-5291-4628-B41C-A463284DD895 Q30384829-55834A04-089C-4DC2-9609-CB6A37E5B750 Q30388575-A96207C0-D19F-42EC-95E6-7AEBAD7F068E Q30680541-8AB39B2D-07C2-4256-AB79-CF69562EF9AC Q33440852-4CFDB09B-7C40-4FC7-B755-463926A70EEA Q33558587-4D175692-574F-43A1-A46F-148D61F87275 Q34067650-ECF4749D-9E54-42ED-878A-AF8A4762B8FB Q34402644-DDC73212-8B1C-4B0B-9955-D998B9CE367E Q34655878-FBC30ABA-C56B-4B5B-BB0C-05FF22A27081 Q34671160-C989D89A-AE0F-4669-8D15-5A77AA8A3E1C Q35515704-19AAEA2F-B0F9-4BAF-A545-4C647B284AAE Q35883043-89D73A25-6789-4B5E-8E91-A0C0892D7A4E Q37031656-2CBB231E-16EA-4E68-BE05-84F833023081 Q37091144-97CDD4A1-0AB0-4A9A-836C-639889F59699 Q37237761-1D350EE1-A836-4278-9985-E64182D39AA7 Q37482566-F32DCB32-F20E-4361-A49C-CA3D2A40451D Q37601946-56056979-87D5-466F-AFE0-8BDCB7EB1BC5 Q37687345-9F61FCE2-09BB-4C48-9D0B-B59EE9B059C5 Q37701881-F99D0893-68F7-41B9-B474-D575D52DEC79 Q37742632-AE403B5A-1DF2-4F61-BAAB-275750E74D02 Q38114116-E13A00EA-F3F9-41CA-B7E0-96562ACE5ED4 Q38152310-307D2E8A-815B-45AD-97CB-D9E9E0AE607D Q38168469-C232F0DA-AE82-461A-92F3-2BD1483CA49B Q38646057-DA4D8227-D540-4038-A550-F3B1016D48B6 Q38783505-5B80185E-6C65-4F6A-96A8-58D22455F4BA Q38783820-A02FE3A6-22B4-4D04-9BEC-3CC9A38398F2 Q38893697-29AF0975-DB09-4AEE-8867-EDDC72830FB5 Q39312161-3B91EB54-9E7A-4290-934A-CB165428A7C7 Q40065733-722F7F64-9E7B-4D6D-AD23-4D275653767A Q49194588-066423E9-A5FB-491A-8EFD-7998E4AE447D Q49983946-A1AE03E0-ED3D-47B7-B69A-4A230F8292C4 Q50147228-DBBA0ED0-DA24-40FC-9A6C-0DBD98C5DFBE Q50191687-A8D082D7-4FB5-4D55-B1F9-278CC2201DE3 Q51052630-38321FB7-0A3E-4385-932B-435D5600BF69 Q57317466-FB3D72B1-DE4C-47B9-A7A6-2E564E646D36

P2860

Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.

http://www.wikidata.org/entity/Q33396664

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Ipilimumab in pretreated patie ...... safety and clinical efficacy.

@ast

Ipilimumab in pretreated patie ...... safety and clinical efficacy.

@en

type

label

Ipilimumab in pretreated patie ...... safety and clinical efficacy.

@ast

Ipilimumab in pretreated patie ...... safety and clinical efficacy.

@en

prefLabel

Ipilimumab in pretreated patie ...... safety and clinical efficacy.

@ast

Ipilimumab in pretreated patie ...... safety and clinical efficacy.

@en

P1433

Q33396664-DFA369ED-DDDF-4117-8500-96F2F875F9C8

P1476

Q33396664-F261B2B1-8509-4C3A-9F27-E707AB821CCE

P2093

Q33396664-0D621D2C-DCEF-47E9-B99D-E0CAB3FA59A2

Q33396664-14BAE8FB-8B71-48A1-97AA-DB681CECE178

Q33396664-377EF459-A34F-49C3-9B43-9AE6FC9B67A2

Q33396664-5669499E-5E00-4C71-AAB9-87945D41D022

Q33396664-5E0884E5-0575-4978-83D5-2671ACBB3E52

Q33396664-DA698EE6-79A4-4EC2-BA42-B110F93524BE

Q33396664-DC3BD88D-CA82-4097-A9FD-618431F3A87B

Q33396664-E13101DC-DA01-4513-AE7D-C052938D948E

Q33396664-FAED71C0-3A45-453C-B659-020DAB93A2E1

P2860

Q33396664-0BEC306C-869C-44F1-A8BA-E41FA3B37A8D

Q33396664-0C195384-F575-494A-B3A3-3DC1B6D765BF

Q33396664-107699F5-8FD5-4081-AFE0-415B816CF525

Q33396664-2A568602-1989-439E-8073-8377FC832F46

Q33396664-32A71F5D-4E15-4DE0-9EFD-A5B1C5215365

Q33396664-3403DB67-65A2-4B28-805F-BECBD7EDC141

Q33396664-377A6799-5E56-48CF-9FEE-8010B47794A7

Q33396664-3E2CAC1E-F31A-4564-94D5-4925DFB50CCD

Q33396664-657951A7-E38E-4900-88CD-165FB959C233

Q33396664-74562CEA-83B5-4D2B-A368-2D8A87459DE3

P2888

Q33396664-A042F80D-E305-4ADD-B9A0-662882548DD0

P304

Q33396664-53BB4954-81BE-4F8E-B409-9203B38E1600

P31

Q33396664-5F030DE7-C4E4-40FA-9976-8DE8703884EA

P356

Q33396664-7305DB35-44BF-4F9F-ACE3-174DB222B4F8

P433

Q33396664-85236DFD-520E-483F-BF4C-01ED37C1E685

P478

Q33396664-DD9C56DF-D488-4E9C-814C-968FCCE2BCE1

P50

Q33396664-363BECE5-337B-4230-9B2C-EA70D0AC2F63

Q33396664-4664CE99-085D-4310-9561-63DA2C8FF591

Q33396664-4EDEA7E1-937A-4707-B370-96A9D3E6702A

Q33396664-7198A4F0-4233-4E43-8AD8-37BFD8343B8A

Q33396664-9AF23ABC-9BEA-423D-A548-9D075C384275

Q33396664-AD5ACBD1-75F6-469D-9C6E-866AE2A31D6A

Q33396664-CB14BA47-9AFA-4AFF-9F3B-4A242A14518C

P577

Q33396664-A01CA0BE-ED71-47CF-983F-FD27B1D50210

P5875

Q33396664-F1DC4923-D1C2-4499-869E-E9BA3C46057E

P6179

Q33396664-334187D3-6112-4152-8E72-23CE8032FBD1

P698

Q33396664-8B12B312-F44A-401B-8DC0-164E5BABBC65

P921

Q33396664-FAEF2AAE-80FC-45D6-8393-84A68557A6D7

P356

S00262-011-1089-0

P1433

Cancer Immunology, Immunotherapy

P1476

Ipilimumab in pretreated patie ...... : safety and clinical efficacy

@en

P2093

Angelo Balestrazzi

http://www.w3.org/2001/XMLSchema#string

Anna Maria Di Giacomo

http://www.w3.org/2001/XMLSchema#string

Clelia Miracco

http://www.w3.org/2001/XMLSchema#string

Costanza De Rossi

http://www.w3.org/2001/XMLSchema#string

Laura Ridolfi

http://www.w3.org/2001/XMLSchema#string

Maresa Altomonte

http://www.w3.org/2001/XMLSchema#string

Monica Boitano

http://www.w3.org/2001/XMLSchema#string

Ruggero Ridolfi

http://www.w3.org/2001/XMLSchema#string

Ruth Plummer

http://www.w3.org/2001/XMLSchema#string

P2860

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Management of posterior uveal melanoma.

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

A prognostic model and staging for metastatic uveal melanoma.

Incidence of uveal melanoma in the United States: 1973-1997.

P2888

s00262-011-1089-0

P304

41-48

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-011-1089-0

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P50

Pier Francesco Ferrucci

Riccardo Danielli

V Chiarion-Sileni

Alessandro Testori

P577

2011-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51563758

http://www.w3.org/2001/XMLSchema#string

P6179

1046605974

http://www.w3.org/2001/XMLSchema#string

P698

21833591

http://www.w3.org/2001/XMLSchema#string

P921